Trial · NCT01379183
Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility
NCT01379183, Phase 2, Phase 3, Completed, Mayo Clinic; results first posted 2014-01-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility. Trials, record NCT01379183. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01379183
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility
- NCT number
- NCT01379183
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 40 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Healthy
- Interventions
- Erythromycin, Placebo, Magnetic Resonance Imaging, Barium Sulfate Solution
- First posted
- 2011-06-23
- Last updated
- 2016-03-21
- Results first posted
- 2014-01-27
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Gastric Volume | Approximately 60 minutes after beginning ingestion of fluid volume | A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. MR images of the abdomen were acquired with a torso phased array coil and a 1.5 tesla magnet MRI. Gastric volumes were assessed with an axial 3D axial gradient echo sequence, which imaged the entire stomach in 13 seconds. |
| Secondary | Jejunal Volume | Approximately 60 minutes after beginning ingestion of fluid volume | The jejunum is the section of the small intestine between the duodenum and the ileum. A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath. |
| Secondary | Ileal Volume | Approximately 60 minutes after beginning ingestion of fluid volume | The Ileal is the terminal portion of the small intestine extending from the jejunum to the cecum. A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath. |
| Secondary | Colonic Volume | Approximately 60 minutes after beginning ingestion of fluid volume | A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath. |
| Secondary | Small Intestine Volume | Approximately 60 minutes after beginning ingestion of fluid volume | A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath. |
| Secondary | Small Intestine and Colon Volume | Approximately 60 minutes after beginning ingestion of fluid volume | A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Gastric Volume | Approximately 60 minutes after beginning ingestion of fluid volume | mL | MEAN | |
| SECONDARY | Jejunal Volume | Approximately 60 minutes after beginning ingestion of fluid volume | mL | MEAN | |
| SECONDARY | Ileal Volume | Approximately 60 minutes after beginning ingestion of fluid volume | mL | MEAN | |
| SECONDARY | Colonic Volume | Approximately 60 minutes after beginning ingestion of fluid volume | mL | MEAN | |
| SECONDARY | Small Intestine Volume | Approximately 60 minutes after beginning ingestion of fluid volume | mL | MEAN | |
| SECONDARY | Small Intestine and Colon Volume | Approximately 60 minutes after beginning ingestion of fluid volume | mL | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Gastric Volume | Erythromycin | 262 | Standard Error 52 | mL | |
| Gastric Volume | Placebo | 718 | Standard Error 59 | mL | |
| Jejunal Volume | Erythromycin | 450 | Standard Error 74 | mL | |
| Jejunal Volume | Placebo | 359 | Standard Error 43 | mL | |
| Ileal Volume | Erythromycin | 248 | Standard Error 30 | mL | |
| Ileal Volume | Placebo | 248 | Standard Error 27 | mL | |
| Colonic Volume | Erythromycin | 190 | Standard Error 53 | mL | |
| Colonic Volume | Placebo | 180 | Standard Error 36 | mL | |
| Small Intestine Volume | Erythromycin | 698 | Standard Error 99 | mL | |
| Small Intestine Volume | Placebo | 607 | Standard Error 56 | mL |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Erythromycin | 19 | |
| Overall Study | STARTED | Placebo | 21 | |
| Overall Study | COMPLETED | Erythromycin | 19 | |
| Overall Study | COMPLETED | Placebo | 21 | |
| Overall Study | NOT COMPLETED | Erythromycin | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Erythromycin | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Erythromycin | 0 | 20 |
| Total, other adverse events | Placebo | 0 | 20 |
| Total, serious adverse events | Erythromycin | 0 | 20 |
| Total, serious adverse events | Placebo | 0 | 20 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P01DK068055 | Pathobiology of the Enteric System | FARRUGIA, GIANRICO; BHARUCHA, ADIL E. | MAYO CLINIC ROCHESTER | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2004 to 2019 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Erythromycin vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01379183
GET https://conductscience.org/api/trials/v1/NCT01379183/registered